NMRA-140 is under clinical development by Neumora Therapeutics and currently in Phase II for Major Depressive Disorder. According to GlobalData, Phase II drugs for Major Depressive Disorder have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NMRA-140’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NMRA-140 overview

NMRA-140 is under development for the treatment of major depressive disorder (MDD) with anhedonia. The drug candidate is a small molecule that acts by targeting kappa-type opioid receptor (KOR). It is administered through oral route.

Neumora Therapeutics overview

Neumora Therapeutics formerly RBNC Therapeutics, is a biotechnology company that uses data science and neuroscience to develop precision medications to treat brain diseases. Neumora Therapeutics is headquartered in Watertown, Massachusetts, the US.

For a complete picture of NMRA-140’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.